Abstract

The plant-derived sesquiterpene lactone micheliolide was recently found to possess promising antileukemic activity, including the ability to target and kill leukemia stem cells. Efforts toward improving the biological activity of micheliolide and investigating its mechanism of action have been hindered by the paucity of preexisting functional groups amenable for late-stage derivatization of this molecule. Here, we report the implementation of a probe-based P450 fingerprinting strategy to rapidly evolve engineered P450 catalysts useful for the regio- and stereoselective hydroxylation of micheliolide at two previously inaccessible aliphatic positions in this complex natural product. Via P450-mediated chemoenzymatic synthesis, a broad panel of novel micheliolide analogs could thus be obtained to gain structure–activity insights into the effect of C2, C4, and C14 substitutions on the antileukemic activity of micheliolide, ultimately leading to the discovery of “micheliologs” with improved potency against acute myelogenic leukemia cells. These late-stage C–H functionalization routes could be further leveraged to generate a panel of affinity probes for conducting a comprehensive analysis of the protein targeting profile of micheliolide in leukemia cells via chemical proteomics analyses. These studies introduce new micheliolide-based antileukemic agents and shed new light onto the biomolecular targets and mechanism of action of micheliolide in leukemia cells. More broadly, this work showcases the value of the present P450-mediated C–H functionalization strategy for streamlining the late-stage diversification and elucidation of the biomolecular targets of a complex bioactive molecule.

Highlights

  • Sesquiterpene lactones (SQLs) constitute a family of bioactive natural products isolated from various plants.[1]

  • We found that FL#62, an engineered variant of the fatty acid monooxygenase P450BM3 (Bacillus megaterium),[44,45] is able to oxidize parthenolide[9] and a broad range of bulky terpenes.[38,46]

  • Along with functionalization of the C4 position, these chemoenzymatic routes have enabled the synthesis and evaluation of a broad panel of C2, C14, and disubstituted MCL analogs, providing comprehensive structure−activity data on the effect of substitutions at multiple sites across the complex natural products on its antileukemic properties. These studies revealed that both C2 and C14 constitute key sites for potentiating the antileukemic activity of MCL, resulting in the discovery of MCL analogs such as MCL-13 and MCL-19 with significantly enhanced antileukemic activity against both leukemia stem cells (M9-ENL1) and patient-derived primary acute myeloid leukemia (AML) cells

Read more

Summary

■ INTRODUCTION

Sesquiterpene lactones (SQLs) constitute a family of bioactive natural products isolated from various plants.[1]. We have generated a collection of over 800 functionally diverse P450 variants via site-saturation mutagenesis of first-sphere activesite residues (74, 75, 78, 81, 82, 87, 180, 181, 184, 263, and 328; Figure 1b) in FL#62 (or derivative thereof), followed by high-throughput fingerprinting of these variants using a panel of structurally diverse chromogenic probes.[9,38,46] As part of this work, we have reported methods for predicting P450 reactivity based on the analysis of their fingerprints via single component (SCA)[9,46] and multicomponent analysis (MCA).[9,38] In the interest of expanding the toolbox of high throughput methods for expediting the development of P450 catalysts with finetuned selectivity, we sought to develop a complementary fingerprint-based strategy (called “regio-fingerprinting”) that could concurrently relay information about the P450 oxidation activity on a target substrate (i.e., MCL) and the regioselectivity of the P450 enzymes on such substrate.

F A S 17 80 3
■ CONCLUSION
■ ACKNOWLEDGMENTS
■ REFERENCES
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call